MOC • CME • NCPD

October 7 • 4:00–5:30

Tailoring Treatment Intensity in HNSCC: The Expanding Role of Cancer Immunotherapy
Robert L. Ferris, MD, PhD

Immunotherapy has become integrated into therapy for many solid tumors. As this new modality has evolved through recurrent/metastatic and recently into the locally advanced setting, new insights and dangers have been encountered, providing insights into complex interactions of conventional modalities with immunotherapeutic modulation of the tumor microenvironment and clinical benefit for patients. The roles of treatment intensification and de-intensification using immunotherapy will be discussed.

MOC • CME • NCPD

October 21 • 4:00–5:00

Oligometastatic Cancers through the Lense of Genitourinary Cancers
Chad Tang, MD

This will be a discussion of the evidence supporting the current application of radiation for oligometastatic cancers, specificallyfocusing on genitourinary cancers.